OACB
Oaktree Acquisition Corp. II · NYSE
Oaktree Acquisition Corp. II (OACB) is a Business Services company listed on NYSE. There were no new wire items for OACB in the last 30 days. The most recent was published Nov 15, 2024.
Latest news
25 items- PRCertain Closed-end Funds Advised by Franklin Templeton Fund Adviser, LLC Announce Appointment of New Chair and DirectorsBrandywineGLOBAL – Global Income Opportunities Fund Inc. ("BWG") Clarion Partners Real Estate Income Fund Inc. ("CPREIF") ClearBridge Energy Midstream Opportunity Fund Inc. ("EMO") LMP Capital and Income Fund Inc. ("SCD") Western Asset Diversified Income Fund ("WDI") Western Asset Emerging Markets Debt Fund Inc. ("EMD") Western Asset Global Corporate Opportunity Fund Inc. ("GDO") Western Asset Global High Income Fund Inc. ("EHI") Western Asset High Income Fund II Inc. ("HIX") Western Asset High Income Opportunity Fund Inc. ("HIO") Western Asset High Yield Defined Opportunity Fund Inc. ("HYI") Western Asset Intermediate Muni Fund Inc. ("SBI") Western Asset Investment
- SECSEC Form 25 filed by Oaktree Acquisition Corp. II25 - Oaktree Acquisition Corp. II (0001820931) (Filer)
- NEWSStocks That Hit 52-Week Lows On ThursdayOn Thursday, 126 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: Amazon.com (NASDAQ:AMZN) was the largest firm on a market cap basis to set a new 52-week low. ThermoGenesis Holdings (NASDAQ:THMO) is the smallest company on a market cap basis to set a new 52-week low. Kinetik Holdings (NASDAQ:KNTK) was the biggest loser of the morning session, as it dropped 51.43% to reach its new 52-week low. Gulf Island Fabrication (NASDAQ:GIFI)'s stock bounced back the most, actually rising 0.0% after reaching its new 52-week low. On Thursday, the following stocks set new 52-week lows: Medtronic (NYSE:MDT) stock set a new 52-week low of $94.31 on Thursday, mo
- SECOaktree Acquisition Corp. II filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - Oaktree Acquisition Corp. II (0001820931) (Filer)
- PRAlvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business CombinationBusiness Combination anticipated to close on or about June 15, 2022 Ordinary shares of Alvotech expected to trade under the new ticker symbol "ALVO" from June 16, 2022 on The Nasdaq Stock Market in New York and from June 23, 2022 on the Nasdaq First North Growth Market in Iceland Warrants expected to trade on The Nasdaq Stock Market in New York under the new ticker symbol "ALVOW" Alvotech Holdings S.A. ("Alvotech S.A."), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II ("OACB") (NYSE:OACB), a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Man
- SECOaktree Acquisition Corp. II filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Oaktree Acquisition Corp. II (0001820931) (Filer)
- PROaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with AlvotechBusiness Combination remains subject to satisfaction of customary closing conditions, including shareholder approval Oaktree Acquisition Corp. II (NYSE:OACB) ("OACB" or the "Company") announced today that, assuming satisfaction of the conditions to the closing of its pending business combination with Alvotech Holdings S.A. and Alvotech ("Topco") (the "Business Combination"), including approval of the Business Combination by the Company's shareholders, Topco, as the surviving entity, intends to list its ordinary shares on The Nasdaq Stock Market LLC and the Nasdaq First North Growth Market (together "Nasdaq") under the new ticker symbol "ALVO" and its warrants on The Nasdaq Stock Market LLC
- NEWSStocks That Hit 52-Week Lows On ThursdayDuring the Thursday's session, 100 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Medtronic (NYSE:MDT) was the largest firm by market cap to set a new 52-week low. Acorda Therapeutics (NASDAQ:ACOR) was the smallest company by market cap to set a new 52-week low. Immunic (NASDAQ:IMUX)'s stock moved significantly downwards, trading down 43.14% to reach a new 52-week low. Sutro Biopharma (NASDAQ:STRO) was the most promising stock of the group, with shares actually trading up 0.0% to bounce back after reaching its new 52-week low. On Thursday, the following stocks set new 52-week lows: Medtronic (NYSE:MDT) shares were up 0.44% for the day, having made
- SECOaktree Acquisition Corp. II filed SEC Form 8-K: Other Events8-K - Oaktree Acquisition Corp. II (0001820931) (Filer)
- NEWSOaktree Acquisition Corp. II Combination Partner Alvotech Highlights AVT04 Clinical StudyThe confirmatory clinical, safety and efficacy study for AVT04, biosimilar candidate to Stelara® (ustekinumab) met its primary endpoint AVT04 (ustekinumab) is part of a broader pipeline of Alvotech’s biosimilars and biosimilar candidates, which includes AVT02 (adalimumab), a biosimilar to Humira® Alvotech is the second company to announce positive top-line results from a patient study utilizing a biosimilar candidate to Stelara® REYKJAVIK, Iceland--(BUSINESS WIRE)-- Alvotech Holdings S.A. (“Alvotech”), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, today announced positive results from a confirmatory clinical s
- PRAlvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®The confirmatory clinical, safety and efficacy study for AVT04, biosimilar candidate to Stelara® (ustekinumab) met its primary endpoint AVT04 (ustekinumab) is part of a broader pipeline of Alvotech's biosimilars and biosimilar candidates, which includes AVT02 (adalimumab), a biosimilar to Humira® Alvotech is the second company to announce positive top-line results from a patient study utilizing a biosimilar candidate to Stelara® Alvotech Holdings S.A. ("Alvotech"), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, today announced positive results from a confirmatory clinical study for AVT04, Alvotech's proposed
- SECOaktree Acquisition Corp. II filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Oaktree Acquisition Corp. II (0001820931) (Filer)
- SECSEC Form 10-Q filed by Oaktree Acquisition Corp. II10-Q - Oaktree Acquisition Corp. II (0001820931) (Filer)
- PRAlvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®- Results from pharmacokinetic (PK) similarity study demonstrate bioequivalence of AVT04 (ustekinumab) to the reference product Stelara® Alvotech Holdings S.A. ("Alvotech"), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, today announced positive top-line results from a pharmacokinetic (PK) study for AVT04, Alvotech's proposed biosimilar to Stelara® (ustekinumab). The PK similarity study (AVT04-GL-101) utilized a single dose, 3-arm, parallel design to compare pharmacokinetics, safety, tolerability, and immunogenicity of a single 45mg/0.5mL subcutaneous dose of AVT04, with US-licensed Stelara®, as well as EU-approve
- NEWSAlvotech Holdings, Oaktree Acquisition Corp. II Set Date For Extraordinary General Meeting Of Shareholders To Approve SPAC Deal As Jun. 7, 2022Alvotech Holdings S.A. (“Alvotech S.A.”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (NYSE:OACB), a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, L.P. (“OACB”), announced today that the extraordinary general meeting of shareholders of OACB (the “Extraordinary General Meeting”) to approve the pending business combination (the “Business Combination”) between Alvotech S.A., Alvotech (“TopCo”) and OACB is scheduled to be held on Tuesday, June 7, 2022 at 10:00 a.m. Eastern time. The Extraordinary General Meeting will be held in p
- PRAlvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business CombinationAlvotech Holdings S.A. ("Alvotech S.A."), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (NYSE:OACB), a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, L.P. ("OACB"), announced today that the extraordinary general meeting of shareholders of OACB (the "Extraordinary General Meeting") to approve the pending business combination (the "Business Combination") between Alvotech S.A., Alvotech ("TopCo") and OACB is scheduled to be held on Tuesday, June 7, 2022 at 10:00 a.m. Eastern time. The Extraordinary General Meeting will be held in
- SECSEC Form DEFM14A filed by Oaktree Acquisition Corp. IIDEFM14A - Oaktree Acquisition Corp. II (0001820931) (Filer)
- SECOaktree Acquisition Corp. II filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Oaktree Acquisition Corp. II (0001820931) (Filer)
- PRAlvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock ExchangeAlvotech and Oaktree Acquisition Corp. II establish financing facilities to enhance the company's capital position and to replace any redeemed capital as part of their proposed merger Parties agree to reduce the minimum cash condition outlined in the merger agreement, thereby enhancing deal certainty in their proposed business combination Alvotech Holdings S.A. ("Alvotech"), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that, subject to the completion of the announced business combination (the "Business Combination") between Alvotech, Alvotech Lux Holdings S.A.S. ("the Company") and Oakt
- SECOaktree Acquisition Corp. II filed SEC Form 8-K: Leadership Update8-K - Oaktree Acquisition Corp. II (0001820931) (Filer)
- SECOaktree Acquisition Corp. II filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Oaktree Acquisition Corp. II (0001820931) (Filer)
- NEWSAlvotech Holdings S.A. Announces Resolution Of Europe Patent Dispute With AbbVieUpon launch, HUKYNDRA® will be one of two citrate-free, high-concentration adalimumab biosimilars on the European market All intellectual-property disputes related to market entry of Alvotech's AVT02 (adalimumab) in the U.S. and Europe are now resolved Alvotech Holdings S.A. ("Alvotech"), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, has today announced the resolution of all intellectual property disputes with AbbVie in Europe and selected markets outside of Europe, related to its AVT02 biosimilar candidate. This paves the way for Alvotech's exclusive strategic partner STADA to commercialize AVT02
- PRAlvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVieUpon launch, HUKYNDRA® will be one of two citrate-free, high-concentration adalimumab biosimilars on the European market All intellectual-property disputes related to market entry of Alvotech's AVT02 (adalimumab) in the U.S. and Europe are now resolved Alvotech Holdings S.A. ("Alvotech"), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, has today announced the resolution of all intellectual property disputes with AbbVie in Europe and selected markets outside of Europe, related to its AVT02 biosimilar candidate. This paves the way for Alvotech's exclusive strategic partner STADA to commercialize AVT02,
- SECSEC Form 10-K filed by Oaktree Acquisition Corp. II10-K - Oaktree Acquisition Corp. II (0001820931) (Filer)
- SECOaktree Acquisition Corp. II filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Oaktree Acquisition Corp. II (0001820931) (Filer)
OACB FAQ
8 questionsWhat does Oaktree Acquisition Corp. II do?
Oaktree Acquisition Corp. II does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the industrial and consumer sectors. The company was incorporated in 2020 and is headquartered in Los Angeles, California.What is the latest news on OACB?
Quantisnow has not tracked any new filings, ratings or press releases for OACB in the last 30 days. The most recent wire item was published on November 15, 2024.Where does OACB stock trade?
Oaktree Acquisition Corp. II (OACB) is listed on NYSE.What sector and industry is OACB in?
Oaktree Acquisition Corp. II operates in the Finance sector, Business Services industry.When did Oaktree Acquisition Corp. II go public?
Oaktree Acquisition Corp. II (OACB) completed its IPO in 2020.What are analysts saying about OACB?
Oaktree Acquisition Corp. II has had 1 recent analyst action on file. The most recent action was from Northland Capital: Outperform with a $15.00 price target on 2022-03-21. Recent price targets cluster around $15.00.What companies are similar to OACB?
Notable peers in the same industry include UBER (Uber Technologies Inc.), BABA (Alibaba Group Holding Limited), MA (Mastercard Incorporated), PDD (PDD Holdings Inc.), V (Visa Inc.). Compare OACB side-by-side with any of them on Quantisnow.How can I track OACB on Quantisnow?
Quantisnow aggregates Oaktree Acquisition Corp. II's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OACB to receive live email and push alerts on every new disclosure.